Spero Therapeutics (SPRO) Announces Earnings Results, Beats Estimates By $0.15 EPS

Share on StockTwits

Spero Therapeutics (NASDAQ:SPRO) posted its quarterly earnings results on Thursday. The company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.75) by $0.15, Fidelity Earnings reports. The business had revenue of $1.69 million during the quarter, compared to the consensus estimate of $0.84 million. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%.

Spero Therapeutics stock opened at $12.98 on Friday. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $19.00. The stock has a market capitalization of $223.33 million, a price-to-earnings ratio of -0.73 and a beta of 2.96.

A number of research analysts recently commented on the company. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 26th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spero Therapeutics in a research note on Tuesday, February 26th. Zacks Investment Research downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. Finally, ValuEngine downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.65.

An institutional investor recently raised its position in Spero Therapeutics stock. Geode Capital Management LLC raised its holdings in Spero Therapeutics Inc (NASDAQ:SPRO) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,842 shares of the company’s stock after acquiring an additional 3,876 shares during the period. Geode Capital Management LLC owned about 0.53% of Spero Therapeutics worth $564,000 at the end of the most recent quarter. 51.00% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4222891/spero-therapeutics-spro-announces-earnings-results-beats-estimates-by-0-15-eps.html.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Read More: Trading Ex-Dividend

Earnings History for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Orchard Therapeutics  to Release Quarterly Earnings on Thursday
Orchard Therapeutics to Release Quarterly Earnings on Thursday
Spero Therapeutics  Announces  Earnings Results, Beats Estimates By $0.15 EPS
Spero Therapeutics Announces Earnings Results, Beats Estimates By $0.15 EPS
Claybrook Capital LLC Takes Position in iShares Expanded Tech-Software Sector ETF
Claybrook Capital LLC Takes Position in iShares Expanded Tech-Software Sector ETF
Edmond DE Rothschild Holding S.A. Boosts Position in TAKE-TWO INTERACTIVE SOFTWARE, INC
Edmond DE Rothschild Holding S.A. Boosts Position in TAKE-TWO INTERACTIVE SOFTWARE, INC
Mercadolibre Inc  Stake Lessened by Edmond DE Rothschild Holding S.A.
Mercadolibre Inc Stake Lessened by Edmond DE Rothschild Holding S.A.
EduCoin Market Capitalization Hits $0.00
EduCoin Market Capitalization Hits $0.00


Leave a Reply

© 2006-2019 Ticker Report